Biogen's president, Stelios Papadopoulos, encouraged by the Alzheimer's trial



[ad_1]

If this last treatment is finally successful, it would be a "big step forward," says Petersen.

"Cure is probably an overvalued goal for Alzheimer's disease but if we could delay the onset of symptoms, slow down the progression." He adds, however, that Petersen noted that only the results of the treatment of Alzheimer's disease have been reported. Biogen and Eisai should publish the detailed results of the final analysis of the mid-range test at future conferences

BAN2401 is one of the two main treatments. Alzheimer's that Biogen and Eisai are pursuing They also develop a drug called aducanumab

"They each have different ways of treating the disease.For the moment we have the intention to continue with both until We see exactly how they work, "said Papadopoulos.

Currently, 5.7 million Americans live with Alzheimer 's disease and this number is expected to increase, according to the Alzheimer' s Association. By 2050, it is expected to reach nearly 14 million people in the United States

– CNT Tae Kim and Reuters contributed to this report.

[ad_2]
Source link